Jiangsu Hengrui Pharmaceuticals Co. Ltd. is the latest mainland China pharmaceutical company to seek a capital raise on the Hong Kong stock exchange, winning clearance April 28 from the China ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

Beijing IP Court issues first ruling on protecting AI model parameters; Chinese pharma companies are using “NewCo” strategy ...

Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments up to $1.77 billion associated with certain development, regulatory and commercial ...

Merck & Co., Inc. (MRK) said on Tuesday that it hasentered into an exclusive license agreement with China-based Jiangsu Hengrui Pharmaceuticals Co. for an investigational oral drug for heart ...

Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui. The most advanced program has results from a Phase 2 test in China suggesting it could be competitive with ...

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, ...

Pacira (PCRX) BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories ...